Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens

Researchers Present Data at Breast Cancer Symposium Showing MammaPrint/BluePrint Can Identify Women Who Benefit from Chemotherapy and Targeted Dual Anti-HER2 Drug Treatment Before Surgery IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia’s MammaPrint® and BluePrint® tests provide new insights that may provide many … Continued